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INTRODUCTION
Barrett’s esophagus (BE) is a condition in
which the stratified squamous epithelium
(SSE) of the distal esophagus undergoes
intestinal metaplasia (transformation to
columnar epithelium), which predisposes
the epithelium to esophageal adenocarci-
noma (EAC) (1). The etiologic consensus
for BE, remains a matter of debate; how-
ever, strong association with chronic gas-
troesophageal reflux disease (GERD) has
been documented (2). An accurate repre-
sentation of the prevalence for BE is still not
clear, most likely due to a lack of protocol
for screening (3). The alarming increase of
EAC by 600% for the past 25 years suggests
that BE has increased as well, as the lat-
ter represents the main risk factor for EAC
(4–6). This emphasizes the importance of
better understanding the causal process
leading to intestinal metaplasia (BE) and
suggests that a possible re-evaluation of
the current protocol for the management




INTRA-GASTRIC pH LEADING TO BILE
SALT TOXICITY
Originally, it was believed that chronic acid
reflux was responsible for BE, as most
patients who develop intestinal metapla-
sia have GERD. However, this may not be
the case, as the increased use of proton
pump inhibitors (PPIs) – introduced in
the late 1980s (7) – appears to be associ-
ated with the increased incidence of EAC
(8, 9). For example, a recent nationwide
case–control study in Denmark showed
that chronic long-term use of PPIs was
associated with a significant increase in the
risk of developing EAC in patients with
BE (10). Thus, it is possible that chronic
PPI use might promote the metaplasia
(BE)-dysplasia-carcinoma (EAC) sequence
(8, 11); however, a mechanistic explana-
tion of the proposed scenario is currently
missing. We hypothesize that (i) a tem-
porally sustained albeit transient increase
in the gastric pH, may cause bile salts to
become soluble in the proximity of the
lower esophageal sphincter (LES) where
they may mobilize to the esophageal tract
during reflux episodes, and (ii) during a
short event of failed acid suppression in
the esophagus, protonated bile salts may
diffuse into the epithelial cells causing the
mucosal metaplasia that could lead to BE.
BILE SALTS VS. BILE ACIDS: WHICH
ARE LIKELY THE MORE POTENT
INDUCERS OF BE IN THE PPI TREATED
GERD?
The mechanism(s) by which bile and var-
ious bile acids (BA) may cause intestinal
metaplasia has yet to be elucidated. While
bile has been shown to reduce squamous
differentiation in primary esophageal cell
lines (12, 13), one of the major ques-
tions remains which of the BA/salts are the
more potent inducers of epithelial meta-
plasia in the esophagus in vivo? Bile salts
are formed in the liver by conjugating BA –
cholic acid (CA) and chenodeoxycholic
acid (CDCA) – with taurine (pKa 2) and
glycine (pKa 3.7) to form tauroconjugates
(TC) and glycoconjugates (GC), respec-
tively. The physiological consequences of
the lower pKa of the bile salts are that by
ionizing in the small intestine (pH of 6–8)
(14), they have better emulsifying proper-
ties and remain in the intestinal lumen due
to their negative charge. In vitro evidence
suggests that the secondary BA, deoxy-
cholic acid, and lithocholic acid, are more
potent inducers of intestinal metaplasia (9,
15), since they are more lipophilic and
readily diffuse across the cell membranes.
However, both the site of formation and
the physico-chemical properties of the sec-
ondary BA make them unlikely candidates
in vivo. First, secondary BA are formed by
intestinal microbiota in the terminal ileum
and the anaerobic bacteria in the colon
(11), which are distal to the foregut and
require a neutral pH environment. Sec-
ond, secondary BA have poor solubility,
and their inability to ionize at the gastric
pH, largely prevents them from reaching
the esophagus in sufficient quantities to
induce metaplasia.
Interestingly, one of the in vitro mech-
anisms by which bile has been shown
to reduce squamous differentiation in
primary esophageal cell lines was via tran-
scriptional up-regulation of the caudal-
type homeobox proteins, Cdx1 and Cdx2.
These transcription factors are known to
promote the proliferation and differenti-
ation of intestinal epithelial cells (12, 13).
Furthermore, Cdx1/2 have been shown to
activate transcription of the apical sodium-
dependent bile acid transporter (ASBT) in
BE (16, 17). ASBT is expressed in the ileum
and has a major role in bile salt reabsorp-
tion. This mechanistic evidence leads us
once more to believe that conjugated BA
(bile salts), rather than secondary BA, are
more likely to induce intestinal metaplasia.
Our hypothesis is further supported by the
relatively low pKa of bile salts compared to
that of BA, which makes the former readily
ionized in the context of the transiently
increased intra-gastric pH environment of
patients with GERD and treated with PPIs.
Finally, a significant number of patients
with BE are overweight (18, 19), and EAC
has the strongest known association with
body mass index (BMI) (20, 21). Therefore,
obese patients may be exposed to higher
levels of bile salts vs. BA, as the production
of the former is dominant in response to
high-lipid intake (98% bile salts, vs. <2%
BA) (22). Importantly, it has been shown
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that patients with reflux disease have higher
concentration of conjugated BA in their
esophageal aspirates (23), especially during
the postprandial periods (24).
STEPS LEADING TO BILE SALTS
ACCESS TO ESOPHAGEAL EPITHELIUM
STEP 1: TRANSIENTLY HIGH-GASTRIC pH
INDUCED BY LONG-TERM PPI TREATMENT
Studies have shown that dose escalation of
PPIs improves intra-gastric pH control (25,
26). The effectiveness of PPIs in control-
ling acid-related symptoms has resulted in
their widespread use (27). However, in such
an environment, the majority of bile salts,
most likely GCs, potentially, may ionize
and mobilize upstream into the esopha-
gus. Thus, patients on long-term PPI treat-
ment, and with a dysfunctional LES, may
be at increased risk for BE and EAC. This
hypothesis may also explain why GERD
patients on PPIs, with a long history of
severe reflux/heartburn (secondary to low-
LES pressure), develop “long-segment” BE
(>3 cm); while patients with a short his-
tory of heartburn (higher LES pressure),
develop “short-segment” BE (<3 cm) (28,
29). Interestingly, in the former, the risk
of EAC has been estimated to be 2–15
times higher (30). In terms of TC, the
same concept applies; however, its ability to
ascend to the esophagus would not require
a higher gastric pH environment (due to
low pKa= 1–2).
STEP 2: LOWER THAN NORMAL ESOPHAGEAL
pH DUE TO ACID REFLUX FACILITATES
DIFFUSION OF THE BILE SALTS IN THE
EPITHELIAL CELLS
The second component of the patho-
genesis that should be considered is the
mechanism by which bile salts cross
the esophageal membrane to promote
epithelial de-differentiation and metapla-
sia. Patients with GERD regardless of how
well they respond to PPI, still endure at least
one reflux episode (intra-esophageal pH
<4) per day. As such, trapped ionized GC
bile salts may become protonated to a more
hydrophobic state, thus, enhancing their
ability to diffuse across the cell membrane
(same concept applies for TC if pH is low
enough). This idea is supported by studies
that have shown that PPIs do not pro-
vide consistent acid suppression. Notably,
in one study, it was reported that the major-
ity of patients with long-segment BE who
received different dosages of esomeprazole
(Nexium), a second-generation PPI, had an
intra-gastric pH>4 for 81–88% of the day
(the higher the dosage the longer the dura-
tion) (26). Importantly, regardless of the
dosage, during a 24-h monitoring period,
up to 5% of the time for >75% of the
patients (>5% for 16–23% of patients) the
intra-esophageal pH was lower than 4.
Overall, we believe that the PPI-induced
increase of the intra-gastric pH to >4
could promote higher levels of conju-
gated BA to reach the esophagus. During
episodes of acid reflux, when the intra-
esophageal pH transiently decreases to<4,
conjugated BA may become protonated
(hydrophobic) and therefore can cross the
esophageal membrane. The “ion-trapping
concept” (pH= pKa+ log I−/U) explains
this phenomenon: the higher than nor-
mal the intra-gastric pH, the greater the
amount of ionized bile salts that will reach
the esophagus; the lower than normal the
intra-esophageal pH, the more bile salts in
un-ionized form that may potentially cross
the epithelial cell membrane (Figure 1A).
HELICOBACTER PYLORI /NSAIDs
ENSURE MAINTENANCE OF AN
INTRA-GASTRIC pH “SAFE-ZONE”
BELOW 4 IN THE CONTEXT OF PPI
TREATMENT
Helicobacter pylori (HP) infection and non-
specific NSAID have been associated with
reduced incidences of esophageal intestinal
metaplasia and adenocarcinoma. Further-
more, this has been observed for patients
who had regularly taken acid-suppressing
medication. The reasons behind this
inverse association remain unknown. Con-
gruent with our hypothesis, we propose
that HP infection and/or NSAIDs may be
countering the effect of acid-suppressing
medications by establishing a steady intra-
gastric pH lower than 4, which we believe
is the “safe-zone” that may limit the reflux
of ionized conjugated BAs (Figure 1B).
NSAIDs
Frequent use of NSAIDs has been strongly
associated with reduced incidence of neo-
plastic progression in patients with BE
(31, 32). The inhibition of cyclooxygenase-
2 (COX-2) – found to be elevated in
epithelial cells of BE during the progres-
sion from low-grade to high-grade dyspla-
sia (precursor to EAC) (33) – has been
proposed as a possible chemoprotective
mechanism (34). However, selective COX-
2 inhibitors had no effect on the inci-
dence of EAC (34–36). Interestingly, non-
selective NSAID (nsNSAID) – especially
aspirin (irreversible COX-1/2 inhibitor) –
are strongly associated with decreased risk
of EAC in patients with BE (37). Further-
more, this protective effect was also evident
with the concomitant use of PPIs, demon-
strating a longitudinal-response relation-
ship – the longer the use, the lower the risk
(34, 38).
Prostaglandins (PG), synthesized by
cyclooxygenase enzymes, have been known
to protect the gastric mucosa and to inhibit
gastric acid secretion. Importantly, PGs
derived from COX-1, but not COX-2, exert
inhibitory effects on acid secretion (39).
Thus, inhibition by non-specific NSAIDs
may theoretically increase acid secretion
in patients on PPI therapy, thereby coun-
tering the acid suppression effect of PPIs
and promoting an intra-gastric pH 2–4.
Further investigation is worth pursuing,
in light of recent evidence demonstrating
aspirin use is associated with risk reduc-
tion for BE in patients with GERD and on
PPI therapy (40).
HELICOBACTER PYLORI
Helicobacter pylori infection, in patients
with GERD, has also been associated with
decreased risk for BE in patients on anti-
reflux medication (PPI or H2RA, at least
once a week), and more protective for
long-segment than short-segment BE (41).
Increased gastric acidity ensued from HP
infection, in subjects on anti-reflux med-
ication, also, may maintain the intra-gastric
pH safe-zone that we proposed to be rele-
vant for preventing bile salts toxicity.
From a global health perspective, in
Japan, the high-HP infection (CagA+
strains) may be causal for the lower fre-
quency of BE (42). However, it should
be noted that compared to the west-
ern world, Japan has a higher prevalence
of gastric non-cardia adenocarcinoma
(GNCA) – strongly correlated with CagA+
HP infection (43) – yet, low incidences
of EAC (44). Furthermore, short-segment
BE is more common in Japan, though
increase in length is observed in older
patients, while long-segment BE are more
prevalent in western countries (45, 46).
The reasons behind these epidemiological
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FIGURE 1 | (A) Illustration of the “ion-trapping concept”: [intra-gastric pH
(PPI induced or physiologic)=pKa (TC or GC)+ log (Ionized TC or
GC/Un-ionized TC or GC)] in which intra-gastric pH, PPI induced (blue) and
physiological (yellow), facilitates movement of tauroconjugates (TC, pKa 2)
and/or glycol-conjugates (GC, pKa 3.7) from the duodenum to the
esophagus. When the intra-gastric pH is >4 (PPI induced), theoretically, 4
times more of the amount of ionized bile salts may mobilize to the
esophagus. Helicobacter pylori (HP) and non-specific (ns) NSAID may
increase acid secretion and shift the intra-gastric pH to lower than 4
(“safe-zone”), thereby preventing bile salt ionization. (B) Anatomical
representation of the location of malignancy with high incidence rate in the
United States, before and after 1975: non-cardia adenocarcinoma (GNCA), in
red, before 1975 when H. pylori infection was high and PPI not in chronic
use; gastric cardia adenocarcinoma (GCA) and esophageal adenocarcinoma
(EAC), in blue, after 1975, with reduced incidence of H. pylori and the
advent of long-term use of PPI. TG, tauroconjugate; GC, glycoconjugate.
differences remain unknown. Nevertheless,
the epidemiologic data raises the possibil-
ity that our hypothesis, supported by the
ion-trapping concept and implying a role
for the bile salts in the pathogenesis of BE
and EA, may apply to the manifestation
of gastric intestinal metaplasia (in gastric
antrum) – a risk factor also strongly asso-
ciated with GNCA and recently linked with
bile (47).
Though gastric carcinogenesis is not
directly addressed by the hypothesis dis-
cussed in this article, it is possible that
the bile salts may have a mechanis-
tic contribution considering the inverse
association between the location of malig-
nancy and the intra-gastric pH. High-acid
secretion (pH 1–2), as rendered by CagA+
strains of HP, may promote bile salt (TG as
the prime contributor) toxicity in the gas-
tric antrum (more proximal to the duode-
num); low-acid secretion (pH >4) as ren-
dered by PPIs, may promote bile salt (GC,
pKa 3.7, as the prime contributor) toxicity
in the gastric cardia and lower esophagus
(more distal to the duodenum). The “ion-
trapping concept”may provide an explana-
tion for HP’s (CagA+ strains) inverse asso-
ciation with adenocarcinomas of the upper
stomach (gastric cardia carcinoma) and
esophagus (EAC) (48, 49), and direct asso-
ciation with adenocarcinoma of the lower
stomach (GNCA) (43, 48) (Figure 1B).
Paralleling the decline in HP infections
and the increased chronic use of PPIs, in
the United States, since 1975, GNCA inci-
dence rate was reduced while GCA has
increased in conjecture with EAC occur-
rence (50).
SIGNIFICANCE
Bile has been shown to induce hyperplasia
and metaplasia of the esophageal epithe-
lium and therefore bile salts may be key
contributors to BE and esophageal cancer.
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In this opinion article, we propose that
an increase in the gastric pH induced by
prolonged use of PPIs may ionize and
hence facilitate bile salts transport to the
esophagus during GERD and their subse-
quent diffusion into the esophageal epithe-
lial cells. Therefore, it may be clinically
relevant to more tightly control the gas-
tric pH in subjects with GERD chronically
treated with PPIs, in particular, in obese
subjects where the bile salt production is
increased. One therapeutic approach to
achieve the balance of the gastric pH below
4 could be the use of combined NSAIDs
and PPI therapy.
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